Meta-analysis Revisiting the Influence of and on Irinotecan Safety in Colorectal Cancer Patients

Overview

Journal Pharmacogenomics

Specialties Genetics
Pharmacology

Date 2024 Aug 22

PMID 39171626

Authors

Cuc Thi Thu Nguyen

Thi Minh Thuy Nguyen

Thanh Huong Phung

Affiliations

Soon will be listed here.

Abstract

To evaluate the association between irinotecan safety and the gene polymorphism in colorectal cancer (CRC) patients. The studies were systematically searched and identified from three databases (PubMed, Embase and The Cochrane Library) until 28 February 2023. The relationships were evaluated using pooled odds ratio (OR). A total of 30 studies out of 600 were included, comprising 4471 patients. was associated with a statistically significant increase in the OR for diarrhea (OR: 1.59, 95% CI = 1.24-2.06 in the additive model; OR = 3.24, 95% CI = 2.01-5.21 in the recessive model; and OR = 1.95, 95% CI = 1.42-2.69 in the dominant model) and neutropenia (OR = 1.70, 95% CI = 1.40-2.06 in the additive model; OR = 4.10, 95%CI = 2.69-6.23 in the recessive model; and OR = 1.93, 95% CI = 1.61-2.31 in the dominant model). Subgroup analysis indicated consistent associations in both Asian and non-Asian populations. was associated with a statistically significant elevation in the OR for diarrhea (only in the recessive model, OR = 2.42; 95% CI = 1.14-5.11) and neutropenia (across all genetic models). The and alleles might be a crucial indicator for predicting irinotecan safety in CRC.

References

Fujita K, Kubota Y, Ishida H, Sasaki Y . Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol. 2015; 21(43):12234-48. PMC: 4649109. DOI: 10.3748/wjg.v21.i43.12234. View

Chen X, Liu L, Guo Z, Liang W, He J, Huang L . UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis. Cancer Chemother Pharmacol. 2017; 79(6):1109-1117. DOI: 10.1007/s00280-017-3306-9. View

Cumpston M, Li T, Page M, Chandler J, Welch V, Higgins J . Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019; 10:ED000142. PMC: 10284251. DOI: 10.1002/14651858.ED000142. View

Huedo-Medina T, Sanchez-Meca J, Marin-Martinez F, Botella J . Assessing heterogeneity in meta-analysis: Q statistic or I2 index?. Psychol Methods. 2006; 11(2):193-206. DOI: 10.1037/1082-989X.11.2.193. View

Xu C, Tang X, Qu Y, Keyoumu S, Zhou N, Tang Y . UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2016; 78(1):119-30. DOI: 10.1007/s00280-016-3057-z. View

Karas S, Innocenti F . All You Need to Know About Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide. JCO Oncol Pract. 2021; 18(4):270-277. PMC: 9014426. DOI: 10.1200/OP.21.00624. View

Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, DAndrea M . The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006; 24(19):3061-8. DOI: 10.1200/JCO.2005.05.5400. View

Nguyen H, Nguyen C, Mai T, Huong P . Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis. Pharmacogenet Genomics. 2023; 33(4):65-78. DOI: 10.1097/FPC.0000000000000490. View

Zhu X, Ma R, Ma X, Yang G . Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis. Biosci Rep. 2020; 40(10). PMC: 7578622. DOI: 10.1042/BSR20200576. View

10.

Marsh S, Hoskins J . Irinotecan pharmacogenomics. Pharmacogenomics. 2010; 11(7):1003-10. PMC: 2927346. DOI: 10.2217/pgs.10.95. View

11.

Kuboki Y, Mizunuma N, Ozaka M, Ogura M, Suenaga M, Shinozaki E . Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer. Oncol Lett. 2012; 2(3):493-498. PMC: 3410456. DOI: 10.3892/ol.2011.260. View

12.

Marques S, Ikediobi O . The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions. Hum Genomics. 2010; 4(4):238-49. PMC: 3525209. DOI: 10.1186/1479-7364-4-4-238. View

13.

Marsh S, McLeod H . Pharmacogenetics of irinotecan toxicity. Pharmacogenomics. 2004; 5(7):835-43. DOI: 10.1517/14622416.5.7.835. View

14.

Liu D, Li J, Gao J, Li Y, Yang R, Shen L . Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC Cancer. 2017; 17(1):437. PMC: 5480170. DOI: 10.1186/s12885-017-3406-2. View

15.

Nelson R, Seligson N, Bottiglieri S, Carballido E, Cueto A, Imanirad I . Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers (Basel). 2021; 13(7). PMC: 8036652. DOI: 10.3390/cancers13071566. View

16.

Glimelius B, Garmo H, Berglund A, Fredriksson L, Berglund M, Kohnke H . Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 2010; 11(1):61-71. PMC: 3036798. DOI: 10.1038/tpj.2010.10. View

17.

de With M, van Doorn L, Kloet E, Van Veggel A, Matic M, de Neijs M . Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clin Pharmacokinet. 2023; 62(11):1589-1597. PMC: 10582127. DOI: 10.1007/s40262-023-01279-7. View

18.

Liu X, Cheng D, Kuang Q, Liu G, Xu W . Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PLoS One. 2013; 8(3):e58489. PMC: 3597733. DOI: 10.1371/journal.pone.0058489. View

19.

Yang Y, Zhou M, Hu M, Cui Y, Zhong Q, Liang L . UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis. Asia Pac J Clin Oncol. 2018; 14(5):e479-e489. DOI: 10.1111/ajco.13028. View

20.

Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R . Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J. 2007; 8(4):278-88. DOI: 10.1038/sj.tpj.6500463. View